Skip to main content
. 2013 Dec 16;11:41. doi: 10.1186/1477-3155-11-41

Table 3.

Effects of ZnPcS 4 -AN-based PDT and/or Dox treatments on plateletgram parameters of healthy and Ehrlich solid tumor-bearing mice

G Treatment PLT (× 10 3 /μL) MPV (fl) P-LCR (%) PDW (fl)
1
NC
1172 ± 50
6.31 ± 0.06
6.4 ± 0.3
6.77 ± 0.04
2
CT
1496 ± 50** a
6.5 ± 0.1
8.1 ± 0.9
6.80 ± 0.07
3
ZnPc
1503 ± 300* a
7.0 ± 0.1** a
9.4 ± 0.5** a
7.3 ± 0.2* a
4
LS
1366 ± 70* a
6.54 ± 0.07
7.8 ± 0.5* a
6.86 ± 0.07
5
PDT
1528 ± 100** a
6.7 ± 0.1
8.4 ± 0.6* a
6.9 ± 0.1
6
Dox
1312 ± 200
6.6 ± 0.3
8 ± 1
6.9 ± 0.3
7
ZnPc/Dox (1)
1219
7.10
12.70
6.90
8
Dox/LS
1808 ± 90** a. * b.d
6.3 ± 0.2* c
7 ± 2
6.53 ± 0.03** a. * b.c.d
9
Dox/PDT
1390 ± 80* h
6.3 ± 0.1** c
6 ± 1** c
6.6 ± 0.1* a.c
  P-values 0.005 0.000 0.026 0.035

Data were expressed as mean ± SEM (standard error of mean). G = Group; PLT = Platelet Count; MPV = Mean Platelet Volume; P-LCR = Platelet Large Cell Ratio; PDW = Platelet Distribution Width; fl = fentoliters. P-values of MPV were generated by ANOVA, while other p-values were generated by Kruskal-Wallis test. Lower-case letters indicate significant diferences in 2-by-2 comparations detected by Bonferroni (MPV) or Mann–Whitney test (other variables), with a = significant compared to group 1; b = significant compared to group 2; c = significant compared to group 3; d = significant compared to group 4; h= significant compared to group 8. Asterisks indicate significant differences (*p < 0.05) or highly significant (**p < 0.01).

(1)Corresponds to the count of only one animal (the other samples coagulated). It was not used in statistical analyses of plateletgram. For details of experimental groups see Table 5.